Skip to Content
Merck
All Photos(1)

Key Documents

SRP3063

Sigma-Aldrich

IGF-Binding Protein 2 human

recombinant, expressed in (BTI-Tn-5B1-4) High-5 Insect Cells, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

Synonym(s):

IBP-2

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
51111800
NACRES:
NA.77

biological source

human

recombinant

expressed in (BTI-Tn-5B1-4) High-5 Insect Cells

Assay

≥98% (HPLC)
≥98% (SDS-PAGE)

form

lyophilized

mol wt

31.5 kDa

packaging

pkg of 20 μg

technique(s)

cell culture | mammalian: suitable

impurities

<0.1 EU/μg endotoxin, tested

color

white to off-white

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... IGFBP2(3485)

General description

IGFBPs (insulin-like growth factor-binding proteins) are mainly required to regulate IGFs (insulin-like growth factors) activities. IGFBP-2 belongs to the IGFBP family of proteins. The protein has a IGF-binding site and a thyroglobulin type-1 domain. It interacts with IGF1 and IGF2. IGFBP-2 is widely expressed in tissues. This gene is mapped to human chromosome 2q35.
Recombinant human IGF-BP2 is a 31.5kDa protein consisting of 289 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Application

IGF-Binding Protein 2 human has been used to study the vaccine-stimulated augmented immunity in the presence of IGFBP-2 in patients with metastatic breast cancer.

Biochem/physiol Actions

IGFBP-2 (insulin-like growth factor-binding protein 2) interacts with integrins and extracellular matrix via arginine-glycine-aspartic acid (RGD) and heparin-binding motifs. It participates in cell detachment, migration and invasion. IGFBP-2 is also associated with various malignancies, including ovarian cancer, breast cancer, colon cancer, lung cancer, prostate cancer, glioma and leukemia. It is suggested as a serum biomarker of Lupus Nephritis and is associated with the chronicity of renal pathology in patients. IGFBP-2 is upregulated in idiopathic pulmonary fibrosis.

Sequence

EVLFRCPPCT PERLAACGPP PVAPPAAVAA VAGGARMPCA ELVREPGCGC CSVCARLEGE ACQVYTPRCG QGLRCYPHPG SELPLQALVM GEGTCEKRRD AEYGASPEQV ADNGDDHSEG GLVENHVDST MNMLGGGGSA GRKPLKSGMK ELAVFREKVT EQHRQMGKGG KHHLGLEEPK KLRPPPARTP CQQELDQVLE RISTMRLPDE RGPLEHLYSL HIPNCDKHGL YNLKQCKMSL NGQRGECWCV NPNTGKLIQG APTIRGDPEC HLFYNEQQEA RGVHTQRMQ

Physical form

Lyophilized from 1x PBS, pH 7.2.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1.
Rinner B, et al.
International Journal of Oncology, 40, 443-443 (2012)
Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis.
Guiot J, et al.
BMC Pulmonary Medicine, 16, 86-86 (2016)
Cheryl A Conover et al.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 13(6), 328-335 (2003-11-20)
Insulin-like growth factor binding protein-2 (IGFBP-2) in its native form had little affinity for extracellular matrix (ECM) derived from human or rat osteoblastic cells. However, in the presence of IGFs, IGFBP-2 binding to ECM was markedly enhanced, with IGF-II being
IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.
Myers AL, et al.
Oncotarget, 6, 25897-25897 (2015)
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
Disis ML, et al.
Journal of Clinical Oncology, 27, 4685-4685 (2009)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service